Abstract
The leukocyte migration inhibition (LMI) assay can be used to detect and quantitate transfer factor (TF) in dialyzable leukocyte extracts (DLE) in vitro. The development of this in vitro assay for TF has in turn permitted the development of a new method for determining the TF potency in different preparations of DLE. The chapter describes and other clinical applications of the LMI assay: (1) documentation of antigen selective defects in cell-mediated immunity (CME), (2) selection of suitable donors for leukocytes for the preparation of DLE for immunotherapy, (3) prediction of the patient's in vivo response to DLE therapy, (4) determination of optimal dosages of DLE for immunotherapy and immunoprophylaxis, and (5) monitoring the patient's response to treatment with DLE. The chapter presents case studies in which DLE is employed containing antigen-specific TF to treat two patients with antigen-selective defects in CMI to either Mycobacterium fortuitum or Candida albicans infections, respectively.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call